-
Press ReleaseTest New ROOT Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press ReleaseNovartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press ReleaseNovartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US
-
Press ReleaseNovartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
-
Press ReleaseNovartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
-
Press ReleaseNovartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
-
Press ReleaseNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
-
Story
Science in Motion: Autumn and Sabrina's Noteworthy Novartis Adventure -
Press ReleaseNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
-
Press ReleaseNew Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
-
Press ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
-
Press ReleaseAktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut